TREMELIMUMAB

4428 reported adverse events

Drug classes: CTLA-4-directed Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking TREMELIMUMAB:

# Side effect Count
0 DEATH 412
1 DIARRHOEA 301
2 MALIGNANT NEOPLASM PROGRESSION 294
3 PYREXIA 228
4 COLITIS 194
5 CYTOKINE RELEASE SYNDROME 175
6 IMMUNE-MEDIATED ENTEROCOLITIS 159
7 RASH 151
8 LIVER DISORDER 133
9 PNEUMONIA 124
See all common reactions for TREMELIMUMAB

TREMELIMUMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARDIOHEPATIC SYNDROME 1 0.3333
1 OESOPHAGOMEDIASTINAL FISTULA 6 0.3000
2 MICROCOCCAL SEPSIS 4 0.2000
3 LIVER CARCINOMA RUPTURED 33 0.1310
4 PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II INCREASED 6 0.0822
5 IMMUNOTOXICITY 9 0.0789
6 CHONDROSARCOMA METASTATIC 2 0.0741
7 BILIARY TRACT INFECTION 36 0.0579
8 TUMOUR HYPERPROGRESSION 13 0.0524
9 IMMUNE-MEDIATED HEPATIC DISORDER 97 0.0497
See all enriched reactions for TREMELIMUMAB